Clinicopathological Factors Determining the Pathological Response to Neoadjuvant Therapy in HER2 Positive Breast Cancer
Aim:In our study, we aimed to determine the clinicopathological factors affecting the pathological response after neoadjuvant chemotherapy in HER2 positive breast cancer.Materials and Methods:A total of 54 HER2 expression positive cases were included in this study. Neoadjuvant chemotherapy regimen c...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Yayincilik
2021-08-01
|
| Series: | Namık Kemal Tıp Dergisi |
| Subjects: | |
| Online Access: |
http://namikkemalmedj.com/archives/archive-detail/article-preview/clinicopathological-factors-determining-the-pathol/48590
|
| _version_ | 1828015891917307904 |
|---|---|
| author | Abdullah Evren YETİŞİR Semra PAYDAŞ |
| author_facet | Abdullah Evren YETİŞİR Semra PAYDAŞ |
| author_sort | Abdullah Evren YETİŞİR |
| collection | DOAJ |
| description | Aim:In our study, we aimed to determine the clinicopathological factors affecting the pathological response after neoadjuvant chemotherapy in HER2 positive breast cancer.Materials and Methods:A total of 54 HER2 expression positive cases were included in this study. Neoadjuvant chemotherapy regimen containing trastuzumab was applied to all patients. Patients’ age, gender, disease stage, tumor size and lymph node status, estrogen and progesterone receptor status, Ki-67 proliferation index, tumor grade, menopausal status and pathological complete response status after neoadjuvant therapy, neoadjuvant treatment regimen and the relationship between the tumor and histological subtype were examined.Results:Grade III tumor, hormone receptor negativity, high Ki-67 score, and the presence of T3 or T4 tumor were found to be better associated with pathological complete response (p=0.036, p=0.033, p=0.021, p=0.048, respectively). High tumor grade, hormone receptor negativity and high Ki-67 score were found as independent risk factors determining pathological complete response (p=0.043, p=0.047, p=0.035, respectively).Conclusion:In this series of 54 cases with HER2 positive breast cancer, the parameters determining pathological complete response after neoadjuvant treatment are high Ki-67 proliferation index, grade III tumor and hormone receptor negativity. |
| first_indexed | 2024-04-10T10:26:36Z |
| format | Article |
| id | doaj.art-5b04ebb633524a79bc3bd7b69884cd41 |
| institution | Directory Open Access Journal |
| issn | 2587-0262 |
| language | English |
| last_indexed | 2024-04-10T10:26:36Z |
| publishDate | 2021-08-01 |
| publisher | Galenos Yayincilik |
| record_format | Article |
| series | Namık Kemal Tıp Dergisi |
| spelling | doaj.art-5b04ebb633524a79bc3bd7b69884cd412023-02-15T16:21:22ZengGalenos YayincilikNamık Kemal Tıp Dergisi2587-02622021-08-019217918310.4274/nkmj.galenos.2021.3293213049054Clinicopathological Factors Determining the Pathological Response to Neoadjuvant Therapy in HER2 Positive Breast CancerAbdullah Evren YETİŞİR0Semra PAYDAŞ1 Adana Şehir Eğitim ve Araştırma Hastanesi, Medikal Onkoloji Kliniği, Adana, Türkiye Çukurova Üniversitesi Tıp Fakültesi, Medikal Onkoloji Anabilim Dalı, Adana, Türkiye Aim:In our study, we aimed to determine the clinicopathological factors affecting the pathological response after neoadjuvant chemotherapy in HER2 positive breast cancer.Materials and Methods:A total of 54 HER2 expression positive cases were included in this study. Neoadjuvant chemotherapy regimen containing trastuzumab was applied to all patients. Patients’ age, gender, disease stage, tumor size and lymph node status, estrogen and progesterone receptor status, Ki-67 proliferation index, tumor grade, menopausal status and pathological complete response status after neoadjuvant therapy, neoadjuvant treatment regimen and the relationship between the tumor and histological subtype were examined.Results:Grade III tumor, hormone receptor negativity, high Ki-67 score, and the presence of T3 or T4 tumor were found to be better associated with pathological complete response (p=0.036, p=0.033, p=0.021, p=0.048, respectively). High tumor grade, hormone receptor negativity and high Ki-67 score were found as independent risk factors determining pathological complete response (p=0.043, p=0.047, p=0.035, respectively).Conclusion:In this series of 54 cases with HER2 positive breast cancer, the parameters determining pathological complete response after neoadjuvant treatment are high Ki-67 proliferation index, grade III tumor and hormone receptor negativity. http://namikkemalmedj.com/archives/archive-detail/article-preview/clinicopathological-factors-determining-the-pathol/48590 breast cancerher2neoadjuvantpathological complete response |
| spellingShingle | Abdullah Evren YETİŞİR Semra PAYDAŞ Clinicopathological Factors Determining the Pathological Response to Neoadjuvant Therapy in HER2 Positive Breast Cancer Namık Kemal Tıp Dergisi breast cancer her2 neoadjuvant pathological complete response |
| title | Clinicopathological Factors Determining the Pathological Response to Neoadjuvant Therapy in HER2 Positive Breast Cancer |
| title_full | Clinicopathological Factors Determining the Pathological Response to Neoadjuvant Therapy in HER2 Positive Breast Cancer |
| title_fullStr | Clinicopathological Factors Determining the Pathological Response to Neoadjuvant Therapy in HER2 Positive Breast Cancer |
| title_full_unstemmed | Clinicopathological Factors Determining the Pathological Response to Neoadjuvant Therapy in HER2 Positive Breast Cancer |
| title_short | Clinicopathological Factors Determining the Pathological Response to Neoadjuvant Therapy in HER2 Positive Breast Cancer |
| title_sort | clinicopathological factors determining the pathological response to neoadjuvant therapy in her2 positive breast cancer |
| topic | breast cancer her2 neoadjuvant pathological complete response |
| url |
http://namikkemalmedj.com/archives/archive-detail/article-preview/clinicopathological-factors-determining-the-pathol/48590
|
| work_keys_str_mv | AT abdullahevrenyetisir clinicopathologicalfactorsdeterminingthepathologicalresponsetoneoadjuvanttherapyinher2positivebreastcancer AT semrapaydas clinicopathologicalfactorsdeterminingthepathologicalresponsetoneoadjuvanttherapyinher2positivebreastcancer |